Browsing by Author "Easterbrook, Philippa"
Now showing items 1-3 of 3
-
Integrating hepatitis B care and treatment with existing HIV services is possible: cost of integrated HIV and hepatitis B treatment in a low-resource setting: a cross-sectional hospital-based cost-minimisation assessment
Ejalu, David Livingstone; Mutyoba, Joan N; Wandera, Claude; Seremba, Emmanuel; Kambugu, Andrew; Muganzi, Alex; Beyagira, Racheal; Amandua, Jacinto; Mugagga, Kaggwa; Easterbrook, Philippa; Ocama, Ponsiano (BMJ, 2022-07-01)Hepatitis B and HIV care share health system challenges in the implementation of primary prevention, screening, early linkage to care, monitoring of therapeutic success and long-term medication adherence. Setting was ... -
Integrating hepatitis B care and treatment with existing HIV services is possible: cost of integrated HIV and hepatitis B treatment in a low-resource setting: a cross-sectional hospital-based cost-minimisation assessment
Ejalu, David Livingstone; Mutyoba, Joan N; Wandera, Claude; Seremba, Emmanuel; Kambugu, Andrew; Muganzi, Alex; Beyagira, Racheal; Amandua, Jacinto; Mugagga, Kaggwa; Easterbrook, Philippa; Ocama, Ponsiano (BMJ Publishing Group Ltd, 2022-07-01)Hepatitis B and HIV care share health system challenges in the implementation of primary prevention, screening, early linkage to care, monitoring of therapeutic success and long-term medication adherence. Arua regional ... -
Lopinavir Plus Nucleoside Reverse-transcriptase Inhibitors, Lopinavir Plus Raltegravir, or Lopinavir Monotherapy for Second-line Treatment of HIV (EARNEST): 144-week Follow-up Results From a Randomised Controlled Trial
Hakim, G. James; Thompson, Jennifer; Kityo, Cissy; Hoppe, Anne; Kambugu, Andrew; van Oosterhout, J Joep; Lugemwa, Abbas; Siika, Abraham; Mwebaze, Raymond; Mweemba, Aggrey; Abongomera, George; Thomason, J Margaret; Easterbrook, Philippa; Mugyenyi, Peter; Walker, A Sarah (Elsevier, 2018-01)Background Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir ...